MAGE-A3 antigen-specific cancer immunotherapeutic

MAGE-A3 antigen-specific cancer immunotherapeutic · GlaxoSmithKline

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for MAGE-A3 antigen-specific cancer immunotherapeutic, covering 2019-06-03 to 2019-06-03. Get the full timeline:

Most recent: Clinical Trial Update: MAGE-A3 Antigen-Specific Cancer Immunotherapeutic in Patients With Progressive Metastatic Cutaneous Melanoma [Phase 2]

See pricing